详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Xu, Rui-hua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Luo, Huiyan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Lu, Jin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18]

; Bai, Yuxian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Mao, Teng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Wang, Jun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18]

; Zhang, Xiaodong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zhu, Yi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18]

; Yang, Qing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zou, Jianjun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ;

机构： [1]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China [2]Sichuan Canc Hosp, Chengdu, Peoples R China [3]Harbin Med Univ, Dept Oncol, Canc Hosp, Harbin, Peoples R China [4]Shanghai Chest Hosp, Shanghai, Peoples R China [5]Hebei Prov Canc Hosp, Dept Radiat Oncol, Shijiazhuang, Hebei, Peoples R China [6]Zhengzhou Univ, Med Oncol, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China [7]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China [8]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [9]Anhui Med Univ, Affiliated Hosp 2, Hefei, Peoples R China [10]Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China [11]Fujian Prov Canc Hosp, Fuzhou, Peoples R China [12]900 Hosp Joint Logist Support Force, Fuzhou, Peoples R China [13]Anhui Med Univ, Affiliated Hosp 1, Hefei, Anhui, Peoples R China [14]Jiangxi Prov Canc Hosp, Nanchang, Jiangxi, Peoples R China [15]Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Affiliated Canc Hosp,Dept Thorac Med, Changsha, Peoples R China [16]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China [17]Jiangsu Hengrui Med Co Ltd, Shanghai, Peoples R China [18]Jiangsu Hengrui Med Co Ltd, Shanghai, Peoples R China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2021]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China [2]Sichuan Canc Hosp, Chengdu, Peoples R China [3]Harbin Med Univ, Dept Oncol, Canc Hosp, Harbin, Peoples R China [4]Shanghai Chest Hosp, Shanghai, Peoples R China [5]Hebei Prov Canc Hosp, Dept Radiat Oncol, Shijiazhuang, Hebei, Peoples R China [6]Zhengzhou Univ, Med Oncol, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China [7]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China [8]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [9]Anhui Med Univ, Affiliated Hosp 2, Hefei, Peoples R China [10]Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China [11]Fujian Prov Canc Hosp, Fuzhou, Peoples R China [12]900 Hosp Joint Logist Support Force, Fuzhou, Peoples R China [13]Anhui Med Univ, Affiliated Hosp 1, Hefei, Anhui, Peoples R China [14]Jiangxi Prov Canc Hosp, Nanchang, Jiangxi, Peoples R China [15]Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Affiliated Canc Hosp,Dept Thorac Med, Changsha, Peoples R China [16]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China [17]Jiangsu Hengrui Med Co Ltd, Shanghai, Peoples R China [18]Jiangsu Hengrui Med Co Ltd, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).

文献详情